CARDAX, INC. (OTCMKTS:CDXI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF
DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY
ARRANGEMENTS OF CERTAIN OFFICERS.

On January 4, 2017, the Board of Directors of Cardax, Inc. (the
Company) elected Michele Galen to serve as a director of
the Company until the Companys next annual meeting of
stockholders. The Board of Directors has determined that Ms.
Galen is an independent director. Ms. Galen will serve on such
committees of the Board of Directors as to be mutually determined
in the future by Ms. Galen and the Board of Directors.

Ms. Galen will receive quarterly equity compensation of $12,500
in arrears in the form of a grant of shares of the Companys
common stock or non-qualified stock options to purchase shares of
the Companys common stock under the Cardax, Inc. 2014 Equity
Compensation Plan based on the higher of the then current market
price or $0.15 per share. Such compensation is subject to
adjustment commensurate with any adjustment of compensation for
the other independent directors of the Company.

Ms. Galen, age 60, serves as a strategic advisor and board member
across pharmaceuticals, biotechnology, health start-ups and
global health, drawing on her broad experience in global
business, communications, law and journalism. From April 2015 to
June 2016, Ms. Galen served as Global Head, Communications and
Public Affairs, for Shire plc, a biotechnology company, where she
served as the lead communications and public affairs advisor on
the successful $32 billion acquisition and integration of
Baxalta. From February 2012 to May 2014, Ms. Galen led Global
Communications for Novartis AG, based in Basel, Switzerland.
During her 14 years with Novartis, Ms. Galen also served on
several management boards in her capacity as Global Head,
Communications and Advocacy, for Novartis Pharmaceuticals; as
Vice President and Global Head, Oncology Affairs; Vice President
and Global Head, Communications and External Affairs for Novartis
Molecular Diagnostics; and Vice President, Corporate
Communications, for US pharmaceuticals. Earlier in her career,
Ms. Galen was a Managing Director in the global public relations
firm Burson-Marsteller. There, she co-founded the Organizational
Change Communications practice. She is an award-winning
journalist, and worked as Legal Editor and Social Issues Editor
at Business Week magazine. Ms. Galen is a member of the New York
State Bar and practiced law at Stroock, Stroock Lavan LLP, and
Skadden, Arps LLP, Slate, Meagher Flom. Ms. Galen currently
serves on the inaugural board of directors of Global Oncology,
and on the advisory board of MKA, a global healthcare consultancy
firm. Formerly, she served as a pro bono advisor to the UNICEF
Office of Public Advocacy, and on the boards of the Global Health
Council and Stupid Cancer. Ms. Galen received a B.A. from George
Washington University, M.S. from the Columbia University Graduate
School of Journalism, and J.D. from New York University School of
Law. She also completed the External Executive Coaching Intensive
at Columbia University.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

About CARDAX, INC. (OTCMKTS:CDXI)

Cardax, Inc. is a life sciences company. The Company develops consumer health and pharmaceutical technologies. The Company is engaged in developing and commercializing anti-inflammatory dietary supplements and drugs. The Company offers ZanthoSyn, a product to help consumers address their inflammatory health. ZanthoSyn is an astaxanthin dietary supplement distributed by the Company. ZanthoSyn features synthetic astaxanthin. Astaxanthin is an ingredient with anti-inflammatory activity that supports joint health, cardiovascular health, metabolic health and liver health. As of December 31, 2015, the Company had two other anti-inflammatory programs with application in various markets, including zeaxanthin esters for macular degeneration and hepatic disease, and lycophyll esters for prostate disease.

CARDAX, INC. (OTCMKTS:CDXI) Recent Trading Information

CARDAX, INC. (OTCMKTS:CDXI) closed its last trading session 00.000 at 0.100 with 8,164 shares trading hands.